Molecular targeted therapies for breast cancer treatment.
Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.
Schlotter
Claus M
CM
Department of Obstetrics and Gynecology, Breast Centre Klinikum Lüdenscheid, Academic Teaching Hospital of the University Bonn, Luedenscheid, Paulmannshoeher Str, 14 - 58515 Luedenscheid Germany.
Vogt
Ulf
U
Allgayer
Heike
H
Brandt
Burkhard
B
D017209:Apoptosis; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D008954:Models, Biological; D016328:NF-kappa B / Q000378:metabolism; D009389:Neovascularization, Pathologic; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D015398:Signal Transduction; D025801:Ubiquitin / Q000378:metabolism
D066246:ErbB Receptors; D016328:NF-kappa B; D046988:Proteasome Endopeptidase Complex; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D025801:Ubiquitin; C508053:ERBB2 protein, human